MedTrace Logo

ZeroOCD: Learn to Overcome Contamination OCD With Your Smartphone

NCT07194473 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2025-09-26

No results posted yet for this study

Summary

This study is a three-arm randomized controlled trial designed to evaluate the efficacy of a smartphone-based augmented reality (AR) cognitive behavioral therapy (CBT) app, called ZeroOCD, for individuals with elevated contamination-related obsessive-compulsive disorder (OCD) symptoms. The AR-CBT app will be compared to both an active control condition (manualized CBT via videoconferencing) and a waitlist control group.

Conditions

  • Obsessive Compulsive Disorder (OCD)

Interventions

BEHAVIORAL

ZeroOCD

The ZeroOCD app contains the following components: psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure with AR, re-exposure with AR, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention

BEHAVIORAL

Videoconferencing CBT

Videoconferencing CBT contains the following chapters: psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention

Sponsors & Collaborators

  • University of Bern

    collaborator OTHER

  • Stockholm University

    collaborator OTHER

  • Thomas More University of Applied Sciences

    collaborator OTHER

  • VU University of Amsterdam

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-21
Primary Completion
2027-05-31
Completion
2027-05-31

Countries

  • Belgium
  • Netherlands
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07194473 on ClinicalTrials.gov